Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Bioventus Inc. before investing.

In this article, we go over a few key elements for understanding Bioventus Inc.’s stock price such as:

• Bioventus Inc.’s current stock price and volume
• Why Bioventus Inc.’s stock price changed recently
• Upgrades and downgrades for BVS from analysts
• BVS’s stock price momentum as measured by its relative strength

About Bioventus Inc. (BVS)

Before we jump into Bioventus Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Want to learn more about Bioventus Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Bioventus Inc..

Bioventus Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Bioventus Inc.’s stock price was $13.170.

Bioventus Inc. is down 0.08% from its previous closing price of $13.180.

During the last market session, Bioventus Inc.’s stock traded between $12.425 and $13.250. Currently, there are approximately 67.30 million shares outstanding for Bioventus Inc..

Bioventus Inc.’s price-earnings (P/E) ratio is currently at 32.7, which is high compared to the Health Care Equipment & Supplies industry median of 31.1. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Bioventus Inc. Stock Price History

Bioventus Inc.’s (BVS) price is currently up 39.51% so far this month.

During the month of July, Bioventus Inc.’s stock price has reached a high of $13.550 and a low of $9.580.

Over the last year, Bioventus Inc. has hit prices as high as $13.550 and as low as $5.810. Year to date, Bioventus Inc.’s stock is up 77.02%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Bioventus Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Bioventus Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Bioventus Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Bioventus Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Bioventus Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Bioventus Inc. (BVS) by visiting AAII Stock Evaluator.

Relative Price Strength of Bioventus Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Bioventus Inc. has a weighted four-quarter relative price strength of 17.13%, which translates to a Momentum Score of 90 and is considered to be Very Strong.

Want to learn more about how Bioventus Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Bioventus Inc. Stock Price: Bottom Line

As of July 31, 2026, Bioventus Inc.’s stock price is $13.170, which is down 0.08% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Bioventus Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.